Abstract
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease — Mineral and BoneDisorder (CKD-MBD). Kidney Int Suppl. 2017;7:1-59.
Highlights
3.1.1: We recommend monitoring serum levels of calcium, phosphate, PTH, and alkaline phosphatase activity beginning in CKD G3a (1C). We suggest such monitoring beginning in CKD G2 (2D)
3.1.3: In patients with CKD G3a–G5D, we suggest that 25(OH)D levels might be measured, and repeated testing determined by baseline values and therapeutic interventions (2C)
We suggest that vitamin D deficiency and insufficiency be corrected using treatment strategies recommended for the general population (2C)
Summary
Доповнення Керівництва з клінічної практики з діагностики, визначення, запобігання та лікування хронічної хвороби нирок із мінеральними та кістковими розладами (ХХН-МКР). Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease — Mineral and Bone Disorder (CKD-MBD). Цитування: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease — Mineral and BoneDisorder (CKD-MBD).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
